CHI FENG CO., LTD. 騏峰塑膠 Terumo [logo placeholder]
Strategic Partnership Proposal · 2025
Terumo×CHI FENG
Total Infusion & Drug Delivery Solutions
Strategic Partnership Proposal
Infusion Therapy Oncology Safety CSTD · OEM/ODM Needle-Free USP <800>
Prepared for Foxconn / 鴻海 Business Development · For discussion with Terumo Corporation
Medical Device
Visual Placeholder
01 / 10
CHI FENG CO., LTD. 騏峰塑膠 Terumo [logo placeholder]
Company Overview · 公司介紹
Why CHI FENG
🏭

37+ Years Medical Plastics Experience

Deep expertise in injection molding for infusion and medical device components · 醫療塑膠射出成型

🔬

ISO 13485 Quality Management System

International medical device quality standard · meets stringent global procurement criteria

🇺🇸

FDA Registered Contract Manufacturer

US market-ready regulatory status · supports partners entering North American channels

⚙️

One-Stop: Design → Mold → Injection → Assembly

Full OEM/ODM capability from concept to finished product · reduces supply chain complexity

🤝

Proven B2B Medical Component Partner

Specialized in infusion-related consumables · trusted supplier for global medical brands

37+
Years of
Medical Plastics
ISO
13485
Quality
Certified
FDA
Reg.
US Market
Ready
02 / 10
CHI FENG CO., LTD. 騏峰塑膠 Terumo [logo placeholder]
Value Proposition · 價值主張
From Product Supplier
to Total Solution Partner
🧱

Component

Precision plastic
injection molding
medical-grade raw material

🔩

Sub-Assembly

Needle-free connectors
vial adapters
extension sets

🔗

Integrated Set

CSTD workflow
infusion system
closed drug transfer

⭐

Total Solution

Infusion · Blood
Oncology Safety
OEM/ODM partner

Flexible Models OEM Supply / ODM Co-development / Private Label
Multiple Departments IV Therapy · Blood · Oncology Safety
Regulatory-Supportive ISO 13485 · FDA Reg. · USP <800> alignment
Speed to Market Faster than building new product lines from scratch
CHI FENG company capability · Strategic partnership discussion context
03 / 10
CHI FENG CO., LTD. 騏峰塑膠 Terumo [logo placeholder]
Product Alignment · 產品機會矩陣
Terumo Opportunity Map: Infusion, Blood & Oncology Safety
Dimension IV Therapy
輸液治療		 Needle-Free
Connector		 High Flow
Connector		 Extension Set
/ Y-site		 Vial Adapter
藥瓶轉接		 CSTD / Oncology
Safety 腫瘤安全
Terumo
Current Line
✓
~
—
✓
~
—
Market
Demand
↑
↑↑
↑↑
↑
↑↑
↑↑↑
CHI FENG
Capability
✓
★
★
✓
★
★
Partnership
Potential		 OEM
Supply		 High
Priority		 New
Product		 OEM
Extension		 CSTD
Anchor		 ★ Strategic
Opportunity
★ CHI FENG can help Terumo fill product gaps and enhance the safety portfolio across infusion, blood, and oncology departments. · ✓ = existing · ↑ = growing demand · — = gap · ~ = partial
04 / 10
CHI FENG CO., LTD. 騏峰塑膠 Terumo [logo placeholder]
Problem Statement · 問題陳述
The Problem: Traditional Drug Compounding
Creates Exposure Risk
💉

Needlestick Injuries

Sharps exposure during drug preparation and administration

Immediate Risk
💧

Drug Leakage & Splash

Liquid hazardous drugs may spill during vial access or transfer

Direct Exposure
🌫️

Aerosolization & Vapor

Airborne drug particles created during compounding pose inhalation risk

Invisible Risk
☣️

Surface Contamination

Hazardous residue on work surfaces, gloves and equipment

Chronic Risk
👩‍⚕️

Occupational Exposure

Pharmacists and nurses face cumulative long-term health risks

Long-term Risk
Key concern: Hazardous drugs — including chemotherapy agents — may cause acute or chronic health effects including rash, reproductive harm, leukemia, genetic mutation, and carcinogenesis. Long-term occupational exposure is often difficult to detect early, and may result in legal liability, compensation claims, and institutional reputation risk.
Source: User-provided material referencing traditional compounding workflow · NIOSH 2004 Hazardous Drugs Alert
05 / 10
CHI FENG CO., LTD. 騏峰塑膠 Terumo [logo placeholder]
Market Intelligence · 市場驅動力
Regulatory & Market Drivers for CSTD
NIOSH 2004

Hazardous Drug Exposure Alert

U.S. NIOSH issued an alert confirming long-term health risks for healthcare workers with prolonged hazardous drug exposure. Established the clinical and policy foundation for CSTD adoption.

USP <800>

Requires CSTD When Dosage Form Allows

USP <800> standard mandates the use of Closed System Transfer Devices where applicable in hazardous drug handling. Enforced in the U.S. from December 2019.

FDA ONB

Dedicated Product Code for CSTD Devices

FDA assigned the ONB product code specifically for CSTD devices, distinguishing them from general infusion products. Facilitates regulatory review and market access.

Market Growth

Rising Oncology Drug Usage Drives Demand

Increasing cancer incidence globally and expansion of hospital oncology departments are directly driving CSTD procurement volumes worldwide.

16.4%
CSTD Market
CAGR (est.)
$6.15B
Market Value
by 2036 (est.)
Global Regional Distribution (est.)
North America — 75%
Europe & Japan — 20%
Others — 5%
CSTD Market Growth Projection (Indexed)
Source: NIOSH 2004 Hazardous Drugs Alert · USP <800> · FDA ONB product code reference from user-provided material · Research Nester market report referenced by user-provided material
06 / 10
CHI FENG CO., LTD. 騏峰塑膠 Terumo [logo placeholder]
Product Solution · 密閉系統解決方案
CHI FENG CSTD Total Solution Workflow
1
💊
Drug Preparation
藥物準備
CSTD Workflow
Image Placeholder

Hazardous drug identified · Pharmacist initiates closed workflow

2
🔌
Vial Adapter
藥瓶轉接器
Vial Adapter
Image Placeholder

Sealed vial access · 13mm / 20mm / 32mm options available

3
🔒
Closed Transfer
密閉轉移裝置
CSTD Device
Image Placeholder

No aerosol escape · Hermetic closed system throughout transfer

4
🔗
Needle-Free
Connector 免針連接
NFC
Image Placeholder

Gen2 neutral pressure design · eliminates sharps risk at connection

5
🩺
Extension Set
延長管組
Extension Set
Image Placeholder

Y-site / multi-site options · compatible with existing infusion systems

6
💉
Infusion Admin.
給藥輸注
Patient Infusion
Image Placeholder

Controlled drug delivery to patient · closed pathway maintained end-to-end

Closed fluid pathway throughout entire process
Reduced leakage and aerosol exposure risk
Protects pharmacists, nurses and patients
Compatible with existing hospital infusion workflow
Source: CHI FENG product capability · USP <800> workflow reference · User-provided CSTD workflow material
07 / 10
CHI FENG CO., LTD. 騏峰塑膠 Terumo [logo placeholder]
Product Lineup · 產品陣容
Infusion Product Portfolio for Terumo
🔗
Gen2 Neutral Pressure Needle-Free Connector
Product Image
Placeholder
Application
IV access · infusion set connection · ICU / ward settings
Value to Terumo
Neutral pressure reduces blood reflux · low dead space · dual closure system
OEM / ODM ✓
⚡
High Flow Needle-Free Connector
Product Image
Placeholder
Application
CT injection · high-flow oncology infusion · specialty care
Value to Terumo
May extend Terumo's premium connector portfolio into high-flow clinical settings
New Product Opportunity
🔌
Vial Adapter 藥瓶轉接器
Product Image
Placeholder
Application
CSTD drug transfer · hazardous drug vial access · oncology pharmacy
Value to Terumo
Anchors Terumo's closed system workflow · critical CSTD entry component
CSTD Anchor Component
🩺
Extension Set / Y-site Connector
Product Image
Placeholder
Application
Standard infusion · multi-drug administration · hospital wards
Value to Terumo
Designed to integrate directly into Terumo infusion sets as OEM components
OEM Supply ✓
🔧
Male Luer / Adapter Connector
Product Image
Placeholder
Application
System connection points · universal infusion compatibility
Value to Terumo
Broad compatibility · can support multiple Terumo product lines as a base component
OEM / Custom ✓
Designed to increase Terumo's product hit rate across IV Therapy, Blood, and Oncology Safety departments · 提高各部門產品命中率
08 / 10
CHI FENG CO., LTD. 騏峰塑膠 Terumo [logo placeholder]
Business Structure · 合作架構
Partnership Model: Foxconn × CHI FENG × Terumo
Foxconn
鴻海 Strategic Gateway
  • Strategic business development enabler
  • Global ecosystem & network access
  • MedTech investment & partnership facilitation
  • Bridge between Taiwan manufacturers and global healthcare brands
Business
Gateway
CHI FENG
騏峰塑膠 Manufacturing Core
  • Component design & mold development
  • Medical-grade injection molding & assembly
  • OEM / ODM manufacturing execution
  • ISO 13485 · FDA Reg. quality system
  • Regulatory-supportive documentation
Taiwan-based · 37+ years experience
OEM Supply /
Co-development
Terumo
Global Clinical Application
  • Global distribution network & market access
  • Clinical application expertise
  • Product portfolio integration
  • Infusion · Blood · Oncology departments
  • Regulatory market authorization
OEM SupplyCHI FENG manufactures, Terumo brands & distributes
ODM Co-developmentJoint product design meeting Terumo clinical specs
Private LabelLocalized manufacturing support for regional markets
Long-term StrategicComponent-to-system integration partnership
09 / 10
CHI FENG CO., LTD. 騏峰塑膠 Terumo [logo placeholder]
Proposed Path Forward · 建議推進步驟
Next Steps Toward Partnership
1

NDA & Scope Confirmation

Sign mutual NDA · align on business scope and department contacts within Terumo · establish communication channel via Foxconn gateway

2

Technical Review with Terumo Teams

Engage Terumo Infusion Department and Blood / Oncology Safety Department · present product technical specifications in detail

3

Product Sample Selection

Provide physical samples of candidate products · Gen2 NFC, High Flow Connector, Vial Adapter, CSTD components · for evaluation

4

Spec & Regulatory Document Review

Share ISO 13485 certification · FDA registration documents · product technical files and test reports for Terumo compliance evaluation

5

Pilot Project & Cost Evaluation

Identify one or two priority products for pilot OEM / ODM engagement · define volume, timeline, pricing and quality benchmark

6

Long-term OEM / ODM Partnership

Formalize strategic supply agreement · explore co-development roadmap · support Terumo's total infusion and oncology safety portfolio expansion

Building a safer, smarter and more integrated infusion future together. 共同打造更安全、更智慧、更整合的輸液未來
10 / 10